Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Cancer Types / Skin Cancers / Kaposi's Sarcoma / NCI Resources
National Cancer Institute®
Last Modified: March 1, 2002
1
UI - 11807324
AU - Murdaca G; Campelli A; Setti M; Indiveri F; Puppo F
TI -
Complete remission of AIDS/Kaposi's sarcoma after treatment with a
combination of two nucleoside reverse transcriptase inhibitors and one
non-nucleoside reverse transcriptase inhibitor.
SO - AIDS 2002 Jan 25;16(2):304-5
2
UI - 11122042
AU - Gonzalez-Beato MJ; Moyano B; Sanchez C; Gonzalez-Beato MT; Perez-Molina
TI -
JA; Miralles P; Lazaro P
Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement
in AIDS-related visceral leishmaniasis.
SO - Br J Dermatol 2000 Dec;143(6):1316-8
AD - Departments of Dermatology, Internal Medicine and Microbiology, G.
Maranon Hospital, C/Dr. Esquerdo 46, 28007 Madrid, Spain.
mgbeato@yahoo.com
A 40-year-old human immunodeficiency virus (HIV)-positive man had three
relapses of visceral leishmaniasis (VL). In the third he developed
nodular skin lesions of three types, some reminiscent of Kaposi's
sarcoma. Biopsy of each type disclosed abundant dermal macrophages with
a huge number of intracellular and extracellular Leishman-Donovan
bodies. Rapid improvement of lesions was achieved after antiparasitic
treatment. AIDS leads to atypical forms of leishmaniasis. Leishmania has
been detected both in normal and pathological skin of these patients due
to dissemination during VL. It is suspected that a considerable
proportion of the population may be infected in endemic areas,
Leishmania being opportunistic in immunosuppressed individuals. It is
important to recognize the range of lesions that may occur in patients
with HIV and VL, many of which are non-specific and may cause diagnostic
difficulty.
3
UI - 11825842
AU - Schwartz MD; Storrow AB
TI -
Clinical pearls: altered mental status and a rash.
SO - Acad Emerg Med 2002 Feb;9(2):152, 158-60
AD - Department of Emergency Medicine, University of Cincinnati, Cincinnati,
OH 45267-0769, USA. schwarmd@fuse.net
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Dr. O'Dwyer discusses pancreatic cancer, family history, screening and future research. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)



